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PrognosticThe rate of hepatitis C virus (HCV) related liver cirrhosis and subsequent cancer development is increasing and
raising the risk of related mortality and morbidity. To address this issue, we aimed to develop a prognostic
index that can be used to stratify patients for risk of disease progression. This index was developed in part by
using a gene signature test implemented in a clinically applicable digital transcript counting platform
(NanoString nCounter system). A cohort of 145 U.S. patients with HCV-related early-stage cirrhosis was analyzed
by using the assay. This dataset (GEO accession number GPL17230) provides information of expression levels of
the prognostic genes in the cohort.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).SpeciﬁcationOrganism/cell
line/tissueHomo Sapiens, tissueSex Male and Female
Sequencer or array type NanoString nCounter assay
Data format Raw data: .txt, Normalized data: SOFT, MINiML, Series
Matrix
(.txt)Experimental factors Gene expression in tissue
Experimental features Gene expression proﬁles were obtained by using total
RNA extracted from formalin-ﬁxed parafﬁn-embedded
liver biopsy tissue specimens.Consent Requirement of consent was waived on condition that
all patients be made anonymousSample source location Mass General Hospital, Boston MA, U.S., 42.3628° N,
71.0686° WDeposited data can be found here: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE54100.
Experimental design, materials and methods
Tissue samples
All of the patient samples were collected from liver biopsies per-
formed atMassachusetts General Hospital. All patients had a histological202, NY, New York, 10029, USA.
).
. This is an open access article underdiagnosis of cirrhosis and had conﬁrmed HCV infection based on positiv-
ity of serum HCV antibody or RNA.RNA preparation
Total RNA was prepared from 10 μm-thick formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue sections by using a High Pure RNA Parafﬁn kit
(Roche) according to the manufacturer's instructions. RNA quality was
assessed by qRT-PCR of a housekeeping gene RPL13A as previously
described [1]. All sampleswere conﬁrmed to have a crossover threshold
(Ct) value less than 33 and an RNA concentration greater than 20 ng/μl,
and 100 to 500 ng total RNA was subjected to the expression proﬁling.NanoString nCounter assay and data normalization
The 186-gene signature deﬁned and validated in our previous stud-
ies [1,2] was implemented in the nCounter digital transcript counting
assay speciﬁcally designed for the analysis of clinical specimen includ-
ing archived FFPE tissue (GEO accession number GPL17230) [3–7]. The
assay was run according to the manufacturer's instruction on a high
sensitivity “green” New Prep Plate, and hybridized cartridges were
scanned using an nCounter Digital Analyzer. Raw transcript count data
were log-transformed (base 2) and scaled by geometric mean of control
probe data (annotated as “normalization_gene”) by using the
NanoString normalizer module implemented in the GenePattern geno-
mic analysis toolkit (www.broadinstitute.org/genepattern). A ﬂoor
value of 1.1 was applied before the log-transformation.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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The 186-gene signature-based outcome prediction was performed
using the nearest template prediction algorithm implemented in the
GenePatternNearest Template Predictionmodule [8] and the prediction
model reported in our initial publication without making any modiﬁca-
tion [1]. The prognostic association of the gene signature-based predic-
tion was evaluated by the Kaplan–Meier curves, log-rank test, and Cox
regression modeling.
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